Poniard Pharmaceuticals, Inc.
PARD
$0.0001
$0.000.00%
OTC PK
| 09/30/2011 | 06/30/2011 | 03/31/2011 | 12/31/2010 | 09/30/2010 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -43.46% | -12.65% | -39.59% | -9.42% | 22.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -47.10% | -35.78% | -66.65% | -68.09% | -35.30% |
| Operating Income | 47.10% | 35.78% | 66.65% | 68.09% | 35.30% |
| Income Before Tax | 41.53% | 41.06% | 72.70% | 60.76% | 34.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 41.53% | 41.06% | 72.70% | 60.76% | 34.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 41.53% | 41.06% | 72.70% | 60.76% | 34.71% |
| EBIT | 47.10% | 35.78% | 66.65% | 68.09% | 35.30% |
| EBITDA | 49.56% | 37.66% | 68.91% | 70.11% | 36.42% |
| EPS Basic | 52.69% | 52.72% | 78.89% | 70.06% | 53.18% |
| Normalized Basic EPS | 60.43% | 52.96% | 74.65% | 74.20% | 52.94% |
| EPS Diluted | 52.69% | 53.15% | 79.00% | 70.06% | 53.18% |
| Normalized Diluted EPS | 60.43% | 52.96% | 74.65% | 74.20% | 52.94% |
| Average Basic Shares Outstanding | 24.26% | 25.30% | 25.04% | 31.04% | 38.74% |
| Average Diluted Shares Outstanding | 24.26% | 25.30% | 25.04% | 31.04% | 38.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -0.70% | -- | 0.02% | -- |